Castle Hook Partners LP Boosts Stake in GE HealthCare Technologies Inc. $GEHC

Castle Hook Partners LP lifted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2,552.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 820,007 shares of the company’s stock after buying an additional 789,096 shares during the quarter. Castle Hook Partners LP’s holdings in GE HealthCare Technologies were worth $67,257,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Banco Bilbao Vizcaya Argentaria S.A. grew its holdings in GE HealthCare Technologies by 4.7% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 14,464 shares of the company’s stock worth $1,187,000 after acquiring an additional 644 shares during the last quarter. Guggenheim Capital LLC lifted its position in GE HealthCare Technologies by 2.8% during the 4th quarter. Guggenheim Capital LLC now owns 138,041 shares of the company’s stock valued at $11,322,000 after acquiring an additional 3,807 shares during the period. DV Equities LLC purchased a new position in GE HealthCare Technologies during the 4th quarter valued at about $52,000. J. Goldman & Co LP purchased a new position in GE HealthCare Technologies during the 4th quarter valued at about $6,681,000. Finally, Abel Hall LLC purchased a new position in GE HealthCare Technologies during the 4th quarter valued at about $236,000. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Down 3.3%

Shares of GEHC opened at $61.15 on Thursday. GE HealthCare Technologies Inc. has a 12-month low of $58.75 and a 12-month high of $89.77. The business’s 50 day moving average is $65.88 and its 200 day moving average is $74.81. The company has a current ratio of 1.22, a quick ratio of 0.95 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $27.82 billion, a PE ratio of 14.63, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The company had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same period last year, the firm posted $1.01 EPS. GE HealthCare Technologies’s quarterly revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Research analysts expect that GE HealthCare Technologies Inc. will post 4.89 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GEHC has been the subject of several recent analyst reports. Evercore set a $80.00 target price on shares of GE HealthCare Technologies in a report on Thursday, April 30th. BTIG Research decreased their target price on shares of GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Barclays reduced their price target on shares of GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a research note on Thursday, April 30th. HSBC cut their target price on shares of GE HealthCare Technologies from $100.00 to $90.00 in a research report on Thursday, April 30th. Finally, Wells Fargo & Company cut their target price on shares of GE HealthCare Technologies from $97.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies presently has an average rating of “Moderate Buy” and an average target price of $80.21.

Insider Activity at GE HealthCare Technologies

In other GE HealthCare Technologies news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were bought at an average price of $63.01 per share, with a total value of $63,010.00. Following the completion of the purchase, the director directly owned 13,702 shares in the company, valued at $863,363.02. This trade represents a 7.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Rodney F. Hochman purchased 1,618 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were acquired at an average cost of $62.03 per share, for a total transaction of $100,364.54. Following the purchase, the director owned 1,618 shares of the company’s stock, valued at $100,364.54. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 21,847 shares of company stock valued at $1,361,355 over the last quarter. 0.36% of the stock is currently owned by insiders.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.